Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04127058 · ClinicalTrials.gov registry record · Phase 1
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
A Phase 1 study of Schizophrenia and Bipolar I Disorder, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04127058 is a Phase 1 study of Schizophrenia and Bipolar I Disorder that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 12 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04127058, a Phase 1 study of Schizophrenia and Bipolar I Disorder, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
Conditions Studied
Interventions
- DRUG Iloperidone
Study Locations (1)
New Jersey
- Vanda Investigational Site - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2019-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04127058
The ClinicalTrials.gov registry entry for NCT04127058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (95% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Iloperidone is the first listed.
NCT04127058 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04127058 about?
NCT04127058 is a clinical study titled "Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia". This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
What is the current status of trial NCT04127058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-10-07. Estimated completion is 2019-11-27.
What conditions does trial NCT04127058 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar I Disorder.
What interventions are being tested in trial NCT04127058?
The interventions under investigation include: Iloperidone (DRUG).
Who is sponsoring clinical trial NCT04127058?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04127058 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.